synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-17 and is reviewed periodically as new material appears.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== Structure == Human GC is a glycosylated alpha-globulin, 52.92 kDa in size. Its 474 amino acids are encoded by a sequence of 1685 nucleotides (including the nucleotides preceding the protein-coding section, composed of the 5' UTR and 3' UTR) located at 4q13.3. The primary structure contains 28 cysteine residues forming multiple disulfide bonds. GC contains 3 domains. Domain 1 is composed of 10 alpha helices, domain 2 of 9, and domain 3 of 4.
LEDs have many advantages over incandescent light sources, including lower power consumption, reduced waste heat, a longer lifetime, improved physical robustness, smaller sizes, and faster switching. In exchange for these generally favorable attributes, disadvantages of LEDs include electrical limitations to low voltage and generally to DC (not AC) power, the inability to provide steady illumination from a pulsing DC or an AC electrical supply source, and a lesser maximum operating temperature and storage temperature. LEDs are transducers of electricity into light.
The headquarters of the Swiss charity Mine Action FSD, in Kharkiv, was struck by a Russian ballistic missile. The Ukrainian 79th Tavrian Air Assault Brigade claimed to have repelled a major Russian assault on Kurakhove, inflicting losses of 12 motorcycles destroyed, six tanks and seven armoured vehicles damaged, 40 Russian soldiers killed and 37 others injured. Ukrainian media reported that the HUR carried out a cyberattack on several banks operating in Russia and other financial institutions in the country. Ukrainian soldiers of the "Khortytsia" group, based in Kharkiv, shot other Ukrainian soldiers due to "personal" issues, killing three soldiers and wounding four. A GRU officer and his wife were injured in a car bombing in Moscow. The Ukrainians claimed that Russian losses in Vovchansk include the 138th Separate Guards Motor Rifle Brigade, the 83rd Tank Regiment and the 157th Tank Regiment. According to Vitaly Sarantsev, spokesman for Ukraine’s operational-tactical group Kharkiv, "the staff number of motorized rifle brigades in the Russian Federation is up to 5,000 personnel, and tank regiments have 94 units of equipment (tanks)". He claimed that Russian losses (killed, wounded, or captured) for "roughly a division's worth of personnel" were 91 percent.
Sources: en.wikipedia.org
In 1996, Saccharomyces cerevisiae was the first single-celled, eukaryotic organism to have its entire genome sequenced. This sequencing helped confirm the nearly century of work by mycologists and enologists in identifying different strains of Saccharomyces cerevisiae that are used in beer, bread and winemaking. Today there are several hundred different strains of S. cerevisiae identified. Not all of the strains are suitable for winemaking and even among the strains that are, there is debate among winemakers and scientists about the actual magnitude of differences between the various strains and their potential impact on the wine. Even among strains that have demonstrated distinctive difference when compared among young wines, these differences seem to fade and become less distinctive as the wines age. Some distinct difference among various strains include the production of certain "off-flavor" and aromas that may be temporary (but producing a "stinky fermentation") or could stay with the wine and either have to be dealt with through other winemaking means (such as the presence of volatile sulfur compounds like hydrogen sulfide) or leave a faulty wine. Another difference includes the "vigor" or speed of fermentation (which can also be influenced by other factors beyond yeast selection) with some yeast strains having the tendency to do "fast ferments" while others may take longer to get going.
Radar is a radiolocation method used to locate and track aircraft, spacecraft, missiles, ships, vehicles, and also to map weather patterns and terrain. A radar set consists of a transmitter and receiver. The transmitter emits a narrow beam of radio waves which is swept around the surrounding space. When the beam strikes a target object, radio waves are reflected back to the receiver. The direction of the beam reveals the object's location. Since radio waves travel at a constant speed close to the speed of light, by measuring the brief time delay between the outgoing pulse and the received "echo", the range to the target can be calculated. The targets are often displayed graphically on a map display called a radar screen. Doppler radar can measure a moving object's velocity, by measuring the change in frequency of the return radio waves due to the Doppler effect. Radar sets mainly use high frequencies in the microwave bands, because these frequencies create strong reflections from objects the size of vehicles and can be focused into narrow beams with compact antennas. Parabolic (dish) antennas are widely used. In most radars the transmitting antenna also serves as the receiving antenna; this is called a monostatic radar. A radar which uses separate transmitting and receiving antennas is called a bistatic radar.
recognition site A specific motif or sequence, either of nucleotides in a nucleic acid molecule or of amino acids in a protein, that is "recognized" or identified by another protein in order to direct the protein's activity to a specific molecule or location. Recognition motifs may consist of a simple consecutive sequence within a single molecule or may involve multiple non-consecutive motifs, e.g. amino acids in separate parts of the same polypeptide which are brought into juxtaposition by the quaternary structure created during protein folding. Recognition sites often help to distinguish the nucleic acid or protein bearing the motif from other similar molecules and thereby identify it as a valid target for some biochemical activity, or to specify a locus or subregion within the larger macromolecule at which the activity is to occur. In this sense recognition sites are critical for properly localizing proteins to their biochemical targets. A protein's recognition site is often but not necessarily the same as its binding site or target site.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.